personalized medicine
Caris Life Sciences, Elevation Oncology Team on Targeted Drug Development
The companies are working together to mine Caris' multiomic data for new cancer drug targets, sharing drug/diagnostic development costs for chosen candidates.
The new reports link variants in CYP2C19 to the safety and efficacy of two drugs, a commonly prescribed antiplatelet drug and an antidepressant.
Lucence Launches US Validation Study for Liquid Biopsy in Lung Cancer
The study will recruit 200 non-small cell lung cancer patients, comparing results of the company's ctDNA testing to tissue next-generation sequencing.
Guardant Health Q1 Revenues up 17 Percent
The company reported 18,390 tests to clinical customers and 3,522 tests to biopharmaceutical customers, an increase of 21 percent and a decrease of 33 percent, respectively.
Burning Rock Biotech, Abbisko Therapeutics Ink CDx Partnership for ABSK091
Burning Rock will use its sequencing platform to identify urothelial carcinoma patients with FGFR alterations, supporting development of Abbisko's drug.